PURPOSE: Pretargeted therapy with radiolabelled bivalent haptens and bispecific antibodies has shown promising results, but blood clearance of the activity-carrying haptens under conditions designed for radioimmunotherapy is relatively slow. Thus, the chase of excess circulating bispecific antibody by biotinylation of the bispecific antibody and injection of avidin before hapten administration was tested with a view to increasing tumour-to-blood activity ratios. METHODS: The anti-carcinoembryonic antigen (CEA) x anti-diethylene triamine penta-acetic acid-indium (di-DTPA-indium) bispecific antibody (hMN-14x734) was derivatised with NHS-LC-biotin and injected into LS-174T tumour-bearing nude mice at a dose of 3.5 nmol, followed by avidin and finally by the 125I-labelled di-DTPA-indium hapten (1 nmol). Blood samples were collected, animals sacrificed and tumours and normal tissues counted. RESULTS: Avidin chased up to 72% of the circulating antibody in the liver and the spleen within 30 min. When the labelled hapten was injected 3 h after avidin, tumour to blood ratios measured 3 and 24 h after hapten injection were significantly improved by the chase (3.5-fold), whereas tumour uptake was not significantly reduced. Uptake in normal tissues was unchanged (liver, kidney) or decreased (muscle), with the exception of spleen, in which uptake of both antibody and hapten was increased by the avidin chase. CONCLUSION: The chase strategy reduces hapten concentration in blood and thus should reduce bone marrow exposure. The use of two different recognition systems limits possible interference between the chase and targeting steps.
PURPOSE: Pretargeted therapy with radiolabelled bivalent haptens and bispecific antibodies has shown promising results, but blood clearance of the activity-carrying haptens under conditions designed for radioimmunotherapy is relatively slow. Thus, the chase of excess circulating bispecific antibody by biotinylation of the bispecific antibody and injection of avidin before hapten administration was tested with a view to increasing tumour-to-blood activity ratios. METHODS: The anti-carcinoembryonic antigen (CEA) x anti-diethylene triamine penta-acetic acid-indium (di-DTPA-indium) bispecific antibody (hMN-14x734) was derivatised with NHS-LC-biotin and injected into LS-174T tumour-bearing nude mice at a dose of 3.5 nmol, followed by avidin and finally by the 125I-labelled di-DTPA-indium hapten (1 nmol). Blood samples were collected, animals sacrificed and tumours and normal tissues counted. RESULTS: Avidin chased up to 72% of the circulating antibody in the liver and the spleen within 30 min. When the labelled hapten was injected 3 h after avidin, tumour to blood ratios measured 3 and 24 h after hapten injection were significantly improved by the chase (3.5-fold), whereas tumour uptake was not significantly reduced. Uptake in normal tissues was unchanged (liver, kidney) or decreased (muscle), with the exception of spleen, in which uptake of both antibody and hapten was increased by the avidin chase. CONCLUSION: The chase strategy reduces hapten concentration in blood and thus should reduce bone marrow exposure. The use of two different recognition systems limits possible interference between the chase and targeting steps.
Authors: J P Vuillez; F Kraeber-Bodéré; D Moro; M Bardiès; J Y Douillard; E Gautherot; E Rouvier; J Barbet; F Garban; P Moreau; J F Chatal Journal: Clin Cancer Res Date: 1999-10 Impact factor: 12.531
Authors: E Gautherot; E Rouvier; L Daniel; E Loucif; J Bouhou; C Manetti; M Martin; J M Le Doussal; J Barbet Journal: J Nucl Med Date: 2000-03 Impact factor: 10.057
Authors: D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg Journal: Proc Natl Acad Sci U S A Date: 2000-02-15 Impact factor: 11.205
Authors: Gregory A Wiseman; Bryan Leigh; William D Erwin; Dominick Lamonica; Ellen Kornmehl; Stewart M Spies; Daniel H S Silverman; Thomas E Witzig; Richard B Sparks; Christine A White Journal: Cancer Date: 2002-02-15 Impact factor: 6.860
Authors: G Paganelli; P Magnani; F Zito; E Villa; F Sudati; L Lopalco; C Rossetti; M Malcovati; F Chiolerio; E Seccamani Journal: Cancer Res Date: 1991-11-01 Impact factor: 12.701
Authors: Robert M Sharkey; Habibe Karacay; Heidi Richel; William J McBride; Edmund A Rossi; Ken Chang; Dion Yeldell; Gary L Griffiths; Hans J Hansen; David M Goldenberg Journal: Clin Cancer Res Date: 2003-09-01 Impact factor: 12.531
Authors: M Hosono; M N Hosono; F Kraeber-Bodéré; A Devys; P Thédrez; M Fiche; E Gautherot; J Barbet; J F Chatal Journal: J Nucl Med Date: 1998-09 Impact factor: 10.057
Authors: Nicole Cauchon; Réjean Langlois; Jacques A Rousseau; Guillaume Tessier; Jules Cadorette; Roger Lecomte; Darel J Hunting; Roberto A Pavan; Stefan K Zeisler; Johan E van Lier Journal: Eur J Nucl Med Mol Imaging Date: 2006-09-22 Impact factor: 9.236
Authors: Shuping Dou; John Virostko; Mary Rusckowski; Dale L Greiner; Alvin C Powers; Guozheng Liu Journal: Front Pharmacol Date: 2014-07-24 Impact factor: 5.810